MARKET

FLXN

FLXN

Flexion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.02
+0.50
+4.75%
After Hours: 11.02 0 0.00% 16:00 09/25 EDT
OPEN
10.48
PREV CLOSE
10.52
HIGH
11.08
LOW
10.37
VOLUME
460.48K
TURNOVER
--
52 WEEK HIGH
22.98
52 WEEK LOW
5.01
MARKET CAP
543.27M
P/E (TTM)
-3.0637
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Have Insiders Been Buying Flexion Therapeutics, Inc. (NASDAQ:FLXN) Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Simply Wall St. · 5d ago
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings:Citius Pharmaceuticals (CTXR): $100M.Flexion Therapeutics (FLXN): $300M.SCYNEXIS (SCYX): $200M.Kezar Life Sciences (KZR): $200M.
Seekingalpha · 09/11 20:41
Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial
* Five patients treated in first cohort of Phase 1 clinical trial evaluating the safety and tolerability of FX201; Drug Monitoring Committee (DMC) supported the initiation of the next dosing cohort BURLINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced
GlobeNewswire · 09/08 20:30
Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference. The virtual fireside
GlobeNewswire · 09/03 20:30
Benzinga's Top Upgrades, Downgrades For August 20, 2020
Benzinga · 08/20 14:51
Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors
BURLINGTON, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics at Anthem, to its Board of Directors. "We are delighted to welcome Liz to our Board of Directors
GlobeNewswire · 08/19 14:00
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 25,315 restricted stock units. The Compensation Committee of the Board of Directors approv
GlobeNewswire · 08/07 20:30
Analyzing Flexion Therapeutics's Unusual Options Activity
Shares of Flexion Therapeutics (NASDAQ: FLXN) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $12.23. * Sentiment: BULLISH * Option Type: TRADE * Trade Type: PUT * Expiration Date: 2021-02-19
Benzinga · 08/06 16:27
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FLXN. Analyze the recent business situations of Flexion through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FLXN stock price target is 20.67 with a high estimate of 35.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 195
Institutional Holdings: 48.55M
% Owned: 98.49%
Shares Outstanding: 49.30M
TypeInstitutionsShares
Increased
54
12.90M
New
46
1.41M
Decreased
22
1.83M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Patrick Mahaffy
President/Chief Executive Officer/Director
Michael Clayman
Chief Financial Officer
David Arkowitz
General Counsel/Secretary
Mark Levine
Other
Scott Kelley
Other
Melissa Layman
Other
Kerry Wentworth
Other
Christina Willwerth
Director
Elizabeth Kwo
Independent Director
Scott Canute
Independent Director
Samuel Colella
Independent Director
Heath Lukatch
Independent Director
Sandesh Mahatme
Independent Director
Ann Merrifield
Independent Director
C. Ann Merrifield
Independent Director
Alan Milinazzo
Independent Director
Mark Stejbach
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FLXN
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Flexion Therapeutics Inc stock information, including NASDAQ:FLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FLXN stock methods without spending real money on the virtual paper trading platform.